Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study

Background: Vaccination in patients with multiple sclerosis (MS) treated with immunosuppressive drugs is highly recommended. Regarding COVID-19 vaccination, no specific concern has been raised. Objectives: We aimed to evaluate if COVID-19 vaccination or infection increased the risk of disease activity, either radiological or clinical, with conversion to MS in a cohort of people with a radiologically isolated syndrome (RIS). Methods: This multicentric observational study analyzed patients in the RIS Consortium cohort during the pandemic between January 2020 and December 2022. We compared the occurrence of disease activity in patients according to their vaccination status. The same analysis was conducted by comparing patients’ history of COVID-19 infection. Results: No difference was found concerning clinical conversion to MS in the vaccinated versus unvaccinated group (6.7% vs 8.5%, p > 0.9). The rate of disease activity was not statistically different (13.6% and 7.4%, respectively, p = 0.54). The clinical conversion rate to MS was not significantly different in patients with a documented COVID-19 infection versus non-infected patients. Conclusion: Our study suggests that COVID-19 infection or immunization in RIS individuals does not increase the risk of disease activity. Our results support that COVID-19 vaccination can be safely proposed and repeated for these subjects.

[1]  E. Tzavellas,et al.  Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis , 2023, Multiple sclerosis.

[2]  Joseph J. Breen,et al.  Sequence similarity between SARS-CoV-2 nucleocapsid and multiple sclerosis-associated proteins provides insight into viral neuropathogenesis following infection , 2023, Scientific Reports.

[3]  Jacqueline Palace,et al.  Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination , 2022, Neurology: Neuroimmunology & Neuroinflammation.

[4]  M. Sormani,et al.  Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome , 2022, Annals of neurology.

[5]  B. Casanova,et al.  Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series , 2022, Frontiers in Neurology.

[6]  I. Ismail,et al.  A systematic review of cases of CNS demyelination following COVID-19 vaccination , 2021, Journal of Neuroimmunology.

[7]  V. Tomassini,et al.  Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases , 2021, Frontiers in Neurology.

[8]  Y. Fragoso,et al.  New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19 , 2021, Multiple Sclerosis and Related Disorders.

[9]  P. Vermersch,et al.  Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome , 2021, JAMA network open.

[10]  V. Tomassini,et al.  mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  M. D. Di Battista,et al.  Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report , 2021, Frontiers in Neurology.

[12]  C. Papeix,et al.  Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. , 2021, Revue neurologique.

[13]  M. Etemadifar,et al.  Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient , 2021, Human vaccines & immunotherapeutics.

[14]  A. Achiron,et al.  COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 , 2021, Multiple Sclerosis.

[15]  S. Chilimuri,et al.  COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab , 2021, Vaccines.

[16]  S. Sekaran,et al.  The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2 , 2020, Biochimie.

[17]  G. Comi,et al.  Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. , 2020, Multiple sclerosis.

[18]  M. Tintoré,et al.  Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. , 2020, Neurologia.

[19]  M. Sormani,et al.  Radiologically Isolated Syndrome: 10‐Year Risk Estimate of a Clinical Event , 2020, Annals of neurology.

[20]  J. Sejvar,et al.  Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis , 2019, Neurology.

[21]  A. Winkelmann,et al.  Vaccination in Multiple Sclerosis: Friend or Foe? , 2019, Front. Immunol..

[22]  C. Louapre,et al.  Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. , 2019, Revue neurologique.

[23]  P. Aspelin,et al.  Incidence of Radiologically Isolated Syndrome: A Population-Based Study , 2016, American Journal of Neuroradiology.

[24]  A. Langer-Gould,et al.  Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. , 2014, JAMA neurology.

[25]  À. Rovira,et al.  Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event , 2014, PloS one.

[26]  P. Aspelin,et al.  Radiologically isolated syndrome – incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review , 2013, Multiple sclerosis.

[27]  F. Moore.  INCIDENTAL MRI ANOMALIES SUGGESTIVE OF MULTIPLE SCLEROSIS: THE RADIOLOGICALLY ISOLATED SYNDROME , 2009, Neurology.

[28]  Robert T. Chen,et al.  Vaccinations and risk of central nervous system demyelinating diseases in adults. , 2003, Archives of neurology.

[29]  Amy,et al.  VACCINATIONS AND THE RISK OF RELAPSE IN MULTIPLE SCLEROSIS , 2022 .